LAWRENCEVILLE, NJ--(Marketwire - March 14, 2012) - Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that it has made available via webcast a pre-recorded presentation delivered at an investor event held March 12, 2012, by Dr. Steven K. Libutti, Professor and Vice Chairman, Department of Surgery and Director of the Montefiore-Einstein Center for Cancer Care at the Montefiore Medical Center and the Albert Einstein College of Medicine. Dr. Libutti is Lead Principal Investigator for the Company’s randomized Phase II study of ThermoDox®, a heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation for the treatment of colorectal liver metastases. The event, held in New York City, was hosted by Rodman & Renshaw, LLC.
Interested parties may access the archived webcast on the Company’s website at http://www.celsion.com/events.cfm.
About Celsion Corporation
Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, Kyungpook National University Hospital and the Beijing Cancer Hospital.
For more information on Celsion, visit our website: http://www.celsion.com.
Investor Contact:
David Pitts
Argot Partners
212-600-1902
Email Contact
